Discounted Cash Flow
Biomarin Pharmaceutical Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.1b | $-630.2m | $-376.2m | -56.4% | $-3.80 |
| 2017 | $1.3b (17.6%) | $-117.0m (81.4%) | $-208.0m (44.7%) | -8.9% (84.2%) | $-0.67 (82.4%) |
| 2018 | $1.5b (13.5%) | $-77.2m (34.0%) | $-124.4m (40.2%) | -5.2% (41.9%) | $-0.44 (34.3%) |
| 2019 | $1.7b (14.3%) | $-23.8m (69.1%) | $-96.8m (22.2%) | -1.4% (73.0%) | $-0.13 (70.5%) |
| 2020 | $1.9b (9.2%) | $859.1m (3702.4%) | $-28.9m (70.1%) | 46.2% (3399.5%) | $4.75 (3753.8%) |
| 2021 | $1.8b (-0.8%) | $-64.1m (-107.5%) | $209.0m (821.9%) | -3.5% (-107.5%) | $-0.35 (-107.4%) |
| 2022 | $2.1b (13.5%) | $141.6m (320.9%) | $54.9m (-73.7%) | 6.8% (294.6%) | $0.76 (317.1%) |
| 2023 | $2.4b (15.4%) | $167.6m (18.4%) | $62.6m (13.9%) | 6.9% (2.6%) | $0.89 (17.1%) |
| 2024 | $2.9b (18.0%) | $426.9m (154.6%) | $487.4m (679.0%) | 15.0% (115.8%) | $2.25 (152.8%) |
| 2025 | $3.2b (12.9%) | $348.9m (-18.3%) | $725.0m (48.7%) | 10.8% (-27.6%) | $1.82 (-19.1%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.